Malta - englanti - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - doxycycline hyclate - solution for infusion - doxycycline hyclate 20 mg - antibacterials for systemic use

Malta - englanti - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - doxycycline hyclate - hard capsule - doxycycline hyclate 100 mg - antibacterials for systemic use

Malta - englanti - Medicines Authority

tarchominskie zaklady farmaceutyczne „polfa” spólka akcyjna ul. a. fleminga 2 03-176 warszawa, poland - solution for infusion - doxycycline 20 mg/ml - antibacterials for systemic use

Kanada - englanti - Health Canada

pharmel inc - doxycycline (doxycycline hyclate) - capsule - 100mg - doxycycline (doxycycline hyclate) 100mg - tetracyclines

Kanada - englanti - Health Canada

pharmel inc - doxycycline (doxycycline hyclate) - tablet - 100mg - doxycycline (doxycycline hyclate) 100mg - tetracyclines

Kanada - englanti - Health Canada

dominion pharmacal - doxycycline (doxycycline hyclate) - tablet - 100mg - doxycycline (doxycycline hyclate) 100mg - tetracyclines

Kanada - englanti - Health Canada

dominion pharmacal - doxycycline (doxycycline hyclate) - capsule - 100mg - doxycycline (doxycycline hyclate) 100mg - tetracyclines

Yhdysvallat - englanti - NLM (National Library of Medicine)

g&w laboratories, inc. - doxycycline (unii: n12000u13o) (doxycycline anhydrous - unii:334895s862) - doxycycline anhydrous 50 mg - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, usp and other antibacterial drugs, doxycycline capsules, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections:     rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae.     respiratory tract infections caused by mycoplasma pneumoniae .     lymphogranuloma venereum caused by chlamydia trachomatis .     psittacosis (ornithosis) caused by chlamydophila psittaci .     trachoma caused by chlamydia trachomatis , although the infec

Yhdysvallat - englanti - NLM (National Library of Medicine)

st. mary's medical park pharmacy - doxycycline (unii: n12000u13o) (doxycycline anhydrous - unii:334895s862) - doxycycline anhydrous 100 mg - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, usp and other antibacterial drugs, doxycycline capsules, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections:     rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae.     respiratory tract infections caused by mycoplasma pneumoniae .     lymphogranuloma venereum caused by chlamydia trachomatis .     psittacosis (ornithosis) caused by chlamydophila psittaci .     trachoma caused by chlamydia trachomatis , although the i

Yhdysvallat - englanti - NLM (National Library of Medicine)

owen laboratories, inc. - doxycycline (unii: n12000u13o) (doxycycline anhydrous - unii:334895s862) - doxycycline anhydrous 40 mg - doxycycline 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. no meaningful effect was demonstrated for generalized erythema (redness) of rosacea. this formulation of doxycycline has not been evaluated in the treatment or prevention of infections. doxycycline 40 mg should not be used for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease. to reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, doxycycline 40 mg should be used only as indicated. efficacy of doxycycline 40 mg beyond 16 weeks and safety beyond 9 months have not been established. doxycycline 40 mg has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea. this drug is contraindicated in persons who have shown hypersensitivity to doxycycline or any of the